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Hypertension is an important risk factor for cardiovascular and renal diseases and
has been identified as one of the main causes of mortality worldwide. Hence, factors
contributing to this condition are of physiological and clinical importance. Endothelin-1
(ET-1) is a 21 amino acid peptide produced ubiquitously in the human body that mediates
blood pressure. Vascular-derived ET-1 acts as a potent vasoconstrictor causing an
increase in blood pressure. On the other hand, increases in ET-1 action in the nephron
mediate diuresis and natriuresis, favoring a decrease in blood pressure. Moreover, a
polymorphism, endothelin converting enzyme-1b-C-338A (ECE-1b-C-338A), in the 5′-
regulatory region of the ECE-1 gene that alters ET-1 synthesis has been identified. Thus,
the goal of this study was to investigate the association of the ECE-1b-C-338A
polymorphism with plasma and urinary levels of ET-1 in pre- and stage 1 hypertensives.
The effects of this polymorphism on aerobic exercise training-induced changes in these
variables were also examined. Healthy, sedentary pre- and stage 1 hypertensive older
adults underwent 24 weeks of supervised aerobic exercise training (AEX) after dietary
stabilization. Plasma ET-1, urinary ET-1, and sodium excretion were assessed.
Genotyping was carried out using standard PCR methods. Separate ANCOVAs were
performed using ECE-1 genotype as the independent variable and blood pressure, plasma
ET-1, urinary ET-1, and sodium excretion as dependent variables. Possible confounding
factors such as age and body mass index were used as covariates in the analyses when
appropriate. ANCOVA was used to compare differences in exercise training-induced
changes in all outcome variables between genotype groups after accounting for
confounding variables. Baseline levels of blood pressure, plasma ET-1, urinary ET-1, and
sodium excretion were not significantly different among genotype groups. When
analyzed by carriers of the C allele and AA homozygotes, only plasma levels of ET-1 in
men differed significantly with AA homozygotes exhibiting the greatest levels of plasma
ET-1. After 24 weeks of AEX, there were no significant changes in the main outcome
variables within genotype groups. Neither were these changes significantly different
between genotype groups. These results suggest that the ECE-1b-C-338A gene
polymorphism is associated with plasma levels of ET-1 in men at baseline but not with
urinary levels of ET-1. In addition, this gene variant does not affect AEX-induced
changes in blood pressure, plasma and urinary levels of ET-1, or sodium excretion.
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INTRODUCTION
Hypertension is the chronic elevation of blood pressure that develops slowly over
long periods of time.1 The accompanying rise in arterial pressure causes baroreceptors to
lose their sensitivity such that they reset at a new higher pressure, which effectively
becomes their “normal setting”.1 In the United States, the number of deaths from
hypertension rose 56 percent from 1993 to 2003.2 Moreover, hypertension is an
important risk factor for cardiovascular and renal diseases, such as coronary artery
disease, atherosclerosis, stroke, and kidney failure. The prevalence of hypertension is
unquestionable, yet, the cause of 90-95 percent of the cases of high blood pressure is not
known.2 Endothelin-1 and genetic variants may be among the many factors that
contribute to the incidence of this “silent killer.”
Endothelin-1 (ET-1) is a 21 amino acid peptide originally described as a highly
potent vasoconstrictor produced by endothelial cells. It is now evident that ET-1 is
produced ubiquitously in the human body. ET-1 produced in the vasculature and renal
tubules influences blood pressure. ET-1 produced in these two distinct biological pools
has complex and opposite effects on blood pressure. Vascular-derived ET-1 is
synthesized and secreted by endothelial cells and acts as a potent vasoconstrictor,
potentially causing an increase in blood pressure.3 On the other hand, increases in ET-1
action in the nephron mediate diuresis and natriuresis,4 favoring a decrease in blood
pressure.5
The precursor of the mature peptide ET-1 is big endothelin. Big endothelin is
converted into ET-1 by endothelin converting enzyme (ECE).6 Evidence suggests that the
enhanced expression of ECE increases ET-1 synthesis.7 A polymorphism, ECE-1b-C-
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338A, in the 5′-regulatory region of the ECE-1 gene has been identified.7 The A-allele
has been associated with a higher promoter activity. A study by Funalot et al. found that
older hypertensive women who were homozygous for the A allele had significantly
higher blood pressure.8 In contrast, AC heterozygotes had blood pressure levels similar to
those of CC homozygotes. Thus, they suggested that the A allele may be recessive for
this gene variant in the population.8 Since the AA homozygotes are expected to have the
highest levels of ECE-1 gene expression, the A-allele is associated with higher plasma
levels of ET-1.8
Research suggests that plasma ET-1 is significantly elevated in individuals with
severe hypertension, and cardiovascular and renal diseases.4, 9-12 Moreover, plasma ET-1
levels are correlated with the degree of hypertension in patients with chronic renal
failure.13 Thus, elevated plasma ET-1 may be of pathophysiological significance.12
Limited animal and human evidence suggests that aerobic exercise training (AEX)
reduces the levels of circulating plasma ET-1.14-16 This seems to result in blood pressure
reduction especially in severe hypertensive subjects. Research on urinary ET-1 is limited
when compared to that of plasma ET-1. One existing study suggest a positive correlation
between urinary ET-1 excretion and urinary sodium excretion levels.17 Renal sodium
handling has a major effect on blood volume and blood pressure regulation. A decrease in
ET-1 excretion may be indicative of sodium retention, leading to higher blood volume
and a concomitant increase in blood pressure. Extremely low levels of circulating ET-1
appear in the urine because most (> 99%) of the ET-1 filtered from plasma is subject to
degradation by neutral endopeptidase in the proximal tubule.18 Therefore, urinary ET-1
excretion is indicative of intrarenal ET-1 generation and reduced production may be a
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marker for hypertension.19, 20 Unpublished data from our laboratory suggest that AEX
increases urinary ET-1 and sodium excretion. Hence, AEX seems to favorably modify
ET-1 levels in the renal tubules and the renal and peripheral vasculature.
While a number of studies have investigated the effect of exercise training on
plasma and urinary ET-1, there are no data available on the effect of the ECE-1b-C-338A
polymorphism on these variables at baseline or on their changes with AEX. Since ET-1
mediates its effects in the vasculature through modulation of vascular tone and in the
renal system through modulation of sodium handling, it is important to understand the
influence of this gene polymorphism because it regulates the synthesis and levels of ET-1.
Thus, the goal of this study is to investigate the association of the ECE-1b-C-338A
polymorphism with plasma and urinary levels of ET-1 in pre- and stage 1 hypertensives.
This study will also examine if these associations are influenced by AEX.
4
HYPOTHESES
1. The ECE-1b-C-338A polymorphism will be associated with baseline levels of
blood pressure, plasma and urinary ET-1, and sodium excretion.
a. Compared to individuals who carry at least one C allele, individuals
homozygous for the A allele will have significantly:
i. higher blood pressure
ii. greater plasma ET-1 
iii. lower urinary ET-1 
iv. lower sodium excretion
2. ECE-1b-C-338A polymorphism will be associated with exercise training-induced
changes in blood pressure, plasma and urinary ET-1, and sodium excretion.
a. Compared to individuals who carry at least one C allele, individuals
homozygous for the A allele with exercise training will exhibit the:
i. greatest reduction in blood pressure
ii. greatest reduction in plasma ET-1 
iii. greatest increase in urinary ET-1 




Subjects between the ages of 50 and 75 years were recruited through print and
media advertising and direct mailings from College Park, Maryland and surrounding
areas. The age range was selected to permit the study of a homogenous group of subjects.
Subjects responding to advertisements in newspapers and on the radio underwent a
telephone interview to assess their initial eligibility. Subjects included in the study were
sedentary (regular aerobic exercise < 2 sessions/week and < 20 min/session and regular
resistance exercise < 1 hour per week in the past year, sedentary occupation), nonsmokers,
and non-diabetic (fasting glucose level < 126 mg/dl). They also had an average systolic
blood pressure between 120-159 or a diastolic blood pressure between 80-99 mmHg
(JNC VII Pre- and stage 1 hypertension) while not on medications; had a BMI < 37; had
normal renal function (serum creatinine < 1.5 mg/dl); had a negative exercise test, and
had no other medical conditions that would preclude vigorous exercise. Hypertensive
subjects using antihypertensive medications were tapered off their medications under
physician supervision before participating in the study. All women on hormone
replacement therapy (HRT) agreed to maintain their regimen for the duration of the study.
All subjects signed a written informed consent after the study and potential risks had been
discussed and all subjects’ questions had been answered. The written informed consent




Subjects underwent two screening visits. Subjects’ medical histories were
reviewed on their first laboratory visit to ensure they met the study inclusion criteria.
Subjects had blood samples drawn after a 12-hour overnight fast for blood chemistries,
measurement of lipoproteins, and isolation of DNA. On the second visit, qualified
subjects underwent a physical examination and a physician-supervised maximal treadmill
exercise test (Bruce protocol) to screen for cardiovascular, pulmonary, or other diseases
that would preclude exercise training. Blood pressure, electrocardiogram, and heart rate
were measured before the treadmill test, at the end of each stage, and six minutes after the
test. The test was terminated upon the onset of cardiovascular signs and/or symptoms, or
when the participant could no longer continue. Subjects were included in the study if they
did not exhibit any cardiovascular signs or symptoms.21
Dietary Stabilization
Qualified subjects were stabilized for six weeks on an American Heart
Association (AHA) Step I diet (50-55% of calories from carbohydrates, 30-35 % from fat,
20-25% from protein, 350 mmol/day of cholesterol, and 3 g/day of sodium). This was
necessary because diet has an effect on sodium excretion and blood pressure. Prior to
beginning the baseline testing and the exercise intervention, a registered dietician
instructed the subjects on the principles, application, and maintenance of the AHA Step I
diet. Those who did not adhere to the prescribed diet for the last three weeks of the
stabilization period were required to extend the dietary stabilization period until they
complied and were weight stable for ≥ 3 weeks before undergoing baseline testing.
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Compliance with the level of dietary sodium intake was checked by assessing 24-hour
urinary sodium excretion. Subjects maintained this diet until they completed all testing
and training.
Baseline Testing
At the completion of the dietary stabilization period and before exercise training
began, all qualified subjects completed baseline testing to determine the main outcome
variables.
Body mass index
A Detecto eye-level physician’s scale was used to measure the height and weight
of all subjects. Body mass index (BMI) was calculated as weight (kilograms) divided by
height (meters) squared.
Casual blood pressure measurement
Casual blood pressure was measured on three separate days according to the JNC
VII guidelines.22 The average of the casual blood pressure measurements recorded on the
three separate baseline testing days was the primary outcome variable used in analyses.
Body composition:
Percent body fat was measured using dual-energy X-ray absorptiometry (DPX-L
software version 1.3z; Lunar Radiation, Madision, WI). Subjects were scanned at
medium speed after a 12-hour overnight fast.
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Maximal oxygen consumption (VO2max):
Maximal oxygen consumption (VO2max) was assessed using indirect calorimetry
during a graded exercise test to exhaustion. The test began at 70% of the peak heart rate
achieved on the subject’s previous exercise test and treadmill grade was increased by 2%
every two minutes. Blood pressure, heart rate, and electrocardiogram were monitored.
Oxygen uptake was measured using a computerized VO2 system (Mass Spectrometer
MGA-1100, Marquette Electronics Inc., Milwaukee, WI) and a bi-directional turbine
flow meter (Ventilation Measurement Module VMM-2, Interface Associates, Aliso Viejo,
CA). The test was terminated in accordance with the ACSM termination criteria.21
VO2max was used to derive valid exercise prescriptions specific for the subject for the
exercise training intervention.
Twenty-four hour urine collection:
The 24-hour urine collection period began immediately after the subject’s first
void in the morning. Subjects were asked to collect their urine in marked urine containers
for 24 hours. On the following morning, the 24-hour urine collection period ended upon
the first void. Urine samples were processed and stored at –80°C until analyzed for
urinary ET-1 and sodium excretion.
Other plasma samples:
On a different day, additional blood samples were collected after another 12-hour
overnight fast to assess plasma ET-1 concentration. Blood samples were drawn from each
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subject in a seated position from an antecubital vein and collected in tubes containing
EDTA. Plasma from the blood sample was stored at –80 °C until assays were performed.
ET-1 immunoassay:
To measure either plasma or urinary ET-1, it was first extracted with C18 seppak
cartridges (Waters, Milford, MA). 500 µL of aprotinin was added to 1 mL of thawed
sample to inhibit any further reactions. 600 µL of the original 1 mL sample + aprotinin
was acidified with 600 µL of 0.1% trifluroacetate (TFA) and centrifuged at 3000 rpm for
15 minutes @ 4°C. A column chromatography setup with the C18 seppak cartridges was
equilibrated with 4 mL of 60% acetonitrile in 0.1% TFA and then washed with 10 mL of
0.1% TFA twice. 1 mL of sample supernatant was passed through the column. It was then
washed twice with 10 mL of 0.1% TFA. Liquid waste was thrown out before eluting with
3 mL of 60% acetonitrile in 0.1% TFA to collect desired sample. Samples were
evaporated to dryness. ET-1 assay was performed in duplicate with the Assay Designs’
Human Endothelin-1 TiterZyme Enzyme Immunometric Assay (EIA) kit. Briefly, the
assay involved extracted ET-1 binding to immobilized polyclonal antibody on a
microtiter plate. A labeled polyclonal antibody was added that binds to the ET-1 captured
on the plate. The concentration of ET-1 was measured by observing color generated when
the substrate reacted with the medium. According to the manufacturer, cross-reactivity
with other isoforms of ET-1 was < 0.1%. Intra-assay and inter-assay coefficients of
variance of low ET-1 levels (~4.76 pg/mL) were 8.5% and 8.1%, respectively. Detection
limit was 0.14 pg/mL. Endothelin-1 concentration was determined by using an Emax
Maxline Microplate Reader (Sunnyvale, CA). The plate was read at 450 nm.
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Genotyping the ECE gene polymorphism:
Blood samples (10 mL) drawn into EDTA tubes were used to genotype for the
ECE-1b-C-338A polymorphism. The anti-coagulated whole blood was centrifuged at
3,000 g for 20 minutes. Genomic DNA was isolated using the Genomic DNA
Purification Kit (Gentra Systems, MN). Primers for the ECE-1b-C-338A polymorphism
were: forward, 5'-TAGGGTTATAGGAGAGGGCTCAGG-3' and reverse, 5'-
AAGTATCAGGAAGGTGCCCTCAAT-3'. PCR amplification was carried out in a
reaction volume of 15 µL containing 1.5 µL of PCR Buffer (10X), 0.9 µL of MgCl2 (25
mM), 2.4 µL dNTP (1.25 mM), 0.225 µL of each primer, 0.06 µL of Taq DNA
polymerase, 8.49 µL of deionized water, and 1.2 µL of DNA. PCR was performed using
an initial denaturation at 95°C for 5 minutes, followed by 35 cycles of denaturation at
95°C for 30 seconds, annealed at 56°C for 30 seconds (40 cycles), and extension at 72°C
for 30 seconds. The PCR amplicon was digested overnight at 65ºC using Tsp509 I (New
England BioLabs, MA) followed by electrophoresis for four hours in a gel composed of
3% agarose (FMC, ME). The A allele (presence of the Tsp I restriction site) yielded
fragments of 243 bp, 178 bp, and 25 bp, and the -338C genotype (absence of the Tsp I
restriction site) yielded fragments of 243 bp and 203 bp.
Exercise Training Protocol
The exercise training program consisted of three supervised sessions of aerobic
exercise per week for 24 weeks. Exercise sessions started and concluded with appropriate
warm-up and cool-down activities. Initial training sessions consisted of 20 minutes of
exercise at 50% VO2max. Training duration was increased by five minutes every week
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until 40 minutes of exercise at 50% VO2max were completed each session. Training
intensity was then increased by 5% VO2max every week until an intensity of 70%
VO2max was achieved. Increases in training duration or intensity occurred only if the
subjects completed their level of exercise for three consecutive sessions without
cardiovascular signs or symptoms or unwarranted fatigue. A fourth unsupervised exercise
session was added to the training program for the last 14 weeks of training. Thus, during
weeks 10 through 24, subjects performed aerobic training for 40 minutes at 70% VO2
max, four times per week. Participants were required to maintain their weight within 5%
of their baseline body weight throughout the entire study.
Final Testing
At the completion of exercise training, subjects provided seven-day food records
to ensure dietary compliance. All final tests were performed 36-48 hours after each
subject’s usual exercise session. This was necessary to avoid any acute effects of exercise
on the cardiovascular system and other outcome variables. Subjects continued their
exercise training until all final tests were complete.
Statistical Analyses 
Statistical analysis was performed using SAS version 9.1 (Cary, NC). ANOVA
assumptions of homogeneity of variance and normality were examined. Variables that did
not meet these assumptions were log-transformed before ANCOVAs were performed.
Separate ANCOVAs were performed using ECE-1 genotype (AA, AC, and CC) as the
independent variable and blood pressure, plasma ET-1, urinary ET-1, and sodium
12
excretion as dependent variables. Possible confounding factors such as age and BMI were
used as covariates in the analyses. ANCOVA was used to compare differences in AEX-
induced changes in all outcome variables between genotype groups after accounting for
confounding variables. Statistical significance in AEX-induced changes in outcome
variables was tested using ANCOVA. Significance was established at P < 0.05. Values
were expressed as means ± SEM.
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RESULTS
Baseline Characteristics of Overall Group
This study included a total of 44 subjects (23 men and 21 women) with a mean
age of 59 ± 1 years. Eight of the 21 women were on HRT. Fifty-five percent of the
subjects were Caucasians (n = 24), 36% were African American (n = 16), and the
remaining 9% were Pacific Islanders, Hispanic or Other (n = 4). Table 1 shows the
subject characteristics of the overall group. The mean BMI, VO2max, and HDL and LDL
cholesterol of the overall group were 28.47 ± 0.53 kg/m2, 25.14 ± 0.65 ml/kg/min, 49.03
± 2.90 mg/dL, and 112.08 ± 5.11 mg/dL, respectively. The average blood pressure value
was 133/88 mmHg. All subjects were pre- and stage 1 hypertensive, except two
individuals whose diastolic blood pressure of 102 mmHg classified them as stage 2
hypertensives according to JNC VII guidelines. Data from these two subjects were kept
in the analyses because they did not significantly influence the results. In addition,
although the ranges reported in Table 1 may suggest that some subjects were
normotensive, JNC VII guidelines require normotensive individuals to have both systolic
and diastolic blood pressure below 120 mmHg and 80 mmHg, respectively. All subjects
in the current study had systolic blood pressure between 109 and 159 mmHg and/or
diastolic blood pressure between 77 and 102 mmHg. The average sodium excretion rate
was 112.69 ± 9.23 mmol/d. Average plasma ET-1 level was 3.55 ± 0.52 pg/mL and
average urinary ET-1 level was 2.21 ± 0.29 pg/mL. Normality test revealed an outlier in
the urinary ET-1 data. This data point was excluded in analyses. The frequency of the CC,
CA, and AA genotypes in this study group were 25%, 39%, and 36%, respectively with a
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minor allele frequency of 56% (Table 2). Also presented in Table 2 are the genotype
distribution and allele frequency in men and women.
Values are expressed as means ± SEM.
Table 2. Distribution and allele frequency of the ECE-1b-C-338A polymorphism
Men Women Total
Genotype, % (n)
CC 30.5% (7) 19% (4) 25% (11)
CA 30.5% (7) 48% (10) 39% (17)
AA 39% (9) 33% (7) 36% (16)
Allele frequency
A allele 54% 57% 56%
Table 1. Baseline characteristics of overall group
N Baseline Range
Age, years 44 58.82 ± 0.94 50.00 – 75.00
Body mass index, kg/m² 43 28.47 ± 0.53 21.37 – 35.06
VO2max, ml/kg/min 42 25.14 ± 0.65 17.00 – 33.40
Total body fat, % 39 37.16 ± 1.35 20.50 – 55.50
Triglycerides, mg/dL 39 116.92 ± 9.28 42.00 – 316.00
HDL cholesterol, mg/dL 39 49.03 ± 2.90 27.00 – 112.00
LDL cholesterol, mg/dL 39 112.08 ± 5.11 48.00 – 177.00
SBP, mmHg 36 132.56 ± 1.80 109.40 – 159.20
DBP, mmHg 36 87.84 ± 1.04 77.00 – 102.00
Na+ excretion, mmol/d 42 112.69 ± 9.23 43.00 – 300.00
Plasma ET-1, pg/mL 35 3.55 ± 0.52 0.00 – 11.60
Urinary ET-1, pg/mL 31 2.21 ± 0.29 0.00 – 6.30
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Baseline Differences
Residuals of HDL cholesterol, sodium excretion, plasma ET-1, and urinary ET-1
were not normally distributed. Therefore, these variables were log-transformed prior to
analyses. However, means were presented using original data to allow for meaningful
interpretation of results. Maximal oxygen consumption (P < 0.001), percent total body fat
(P < 0.001), and HDL cholesterol (P = 0.01) differed significantly between men and
women (Table 3). In addition, percent body fat significantly differed among the three
ethnic groups with African-Americans manifesting the highest percent body fat (P =
0.02) (data not shown). Because gender distribution within ethnic groups could confound
results, ethnic differences were analyzed in men and women. Since the “other” ethnic
group was composed of only 4 subjects, it was not included in the sub-analyses. This sub-
analysis revealed that African American women had a significantly higher BMI than
Caucasian women (30.59 ± 1.09 vs. 25.73 ± 0.97, P = 0.01), while African American
men and Caucasian men had similar BMI (27.78 ± 0.67 vs. 28.78 ± 0.79, P = 0.67) (Table
4). Also, there was a tendency towards a significant ethnic difference in urinary levels of
ET-1 in men (3.73 ± 1.29 vs. 1.61 ± 0.39 in African American men and Caucasian men,
respectively, P = 0.05) but not in women (P = 0.13). All other variables were similar
between genders, among ethnic groups, and between African Americans and Caucasians
in men and women.
None of the baseline measures, including the main outcome variables, were
significantly different (P > 0.05) between carriers of the C allele and AA homozygotes
(i.e. CC+CA vs. AA) except for plasma ET-1 (Table 5). Carriers of the C allele had
significantly lower levels of plasma ET-1 compared to AA homozygotes (2.56 ± 0.57 vs.
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4.93 ± 0.94 pg/mL, respectively, P = 0.02). However, when analyzed by the three
genotype groups, plasma levels of ET-1 were not significantly different (P = 0.12). No
covariates were used in the analysis because those considered did not differ between
groups and did not correlate with plasma levels of ET-1. However, AA homozygotes had
higher SBP, DBP, and sodium excretion values although these differences were not
statistically significant.
Similarly, there were no gender specific differences in all variables among
genotype groups except for plasma and urinary ET-1 levels. There was a gender specific
genotype difference in plasma levels of ET-1 in men (2.28 ± 0.73 pg/mL in CC + CA
genotype group vs. 5.80 ± 1.08 pg/mL in AA genotype group, P = 0.01) (Figure 1). While
the AA homozygote men had the highest levels of plasma ET-1, we observed similar
levels of plasma ET-1 in CC homozygotes and CA heterozygotes (1.96 ± 0.65 and 2.72 ±
1.58 pg/mL, respectively, P = 0.64). Plasma levels of ET-1 were similar among genotype
groups in females (Figure 1). There was no significant difference in urinary levels of ET-
1 between carriers of the C allele and AA homozygotes. Of interest, however, was the
finding that CA heterozygotes had the lowest levels of urinary ET-1 (0.98 ± 0.47 pg/mL)
compared to CC homozygotes (2.58 ± 0.96 pg/mL, P = 0.04) and AA homozygotes (2.27
± 0.66 pg/mL, P = 0.02) in men (Figure 2). Although urinary levels of ET-1 differed
significantly between CA heterozygotes and CC and AA homozygotes, this significance
was no longer evident when we accounted for baseline levels of LDL cholesterol. We
covaried for LDL cholesterol because this variable was correlated with urinary ET-1.
When the main outcome variables were analyzed by gender within genotype groups, no
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significant differences were found. Sub-analyses by ethnicity within genotype groups
could not be performed due to small sample size.
There was a significant correlation between sodium excretion and diastolic blood
pressure (r = 0.37; P = 0.03) in the overall group (Table 6). There was also a significant
correlation between plasma ET-1 levels and diastolic blood pressure in the overall group
as well as in the CC+CA group (Table 6). Otherwise, there were no other significant
correlations between any of the main outcome variables in the overall group, and when
analyzed by genotype groups.
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Values are expressed as means ± SEM.
Numbers in parentheses represent sample sizes.
* P < 0.05.
† P < 0.001.
T Represents log-transformed data. Although means ± SEM of original data are shown, the P-value of
analyses with the log-transformed data was reported.
Table 3. Baseline gender differences
Gender
Characteristic Men Women P-value






























































































































































































Values are expressed as means ± SEM
Numbers in parentheses represent sample sizes
* P < 0.05
† P < 0.001
T Represents log-transformed data. Although means ± SEM of original data are shown, the P-value of
analyses with the log-transformed data was reported.
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Values are expressed as means ± SEM.
Numbers in parentheses represent sample sizes.
* P < 0.05.
† P < 0.001.
T Represents log-transformed data. Although means ± SEM of original data are shown, the P-value of
analyses with the log-transformed data was reported.
Table 5. Baseline genotype differences
Genotype
Characteristic CC + CA AA P-value






































































































































Table 6. Correlation coefficients of main outcome variables
Overall Group















































































































































T Represents log-transformed data, Na+ represents sodium.
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Training-induced Changes in Overall Group
Of the 44 subjects, thirty-six (20 men and 16 women) completed the 24 week
aerobic exercise training (AEX) intervention. Fifty-six percent of those completing the
study were Caucasians (n = 20), 33% were African Americans (n = 12), and the
remaining 11% were Pacific Islanders, Hispanic or Other (n = 4). The CC, CA, and AA
genotype frequency in this group was 19%, 39%, and 42%, respectively (Table 7). Also
reported in Table 7 are the genotype distribution and allele frequency in men and women
who completed the AEX intervention.
Presented in Table 8 are the AEX-induced changes in all outcome variables in the
entire group. After AEX, VO2max was significantly elevated (3.80 ± 0.45 ml/kg/min, P <
0.0001), confirming the efficacy of the exercise training protocol. Although there was a
significant reduction in BMI (-0.34 ± 0.11 kg/m², P = 0.004), all changes were within 5%
of the initial body weight as mentioned in the methods section. Concomitantly, there was
a significant reduction in percent body fat (-1.87 ± 0.37 %, P < 0.0001). Though there
was a significant increase in HDL cholesterol (3.00 ± 0.97 mg/dL, P = 0.01) in response
to AEX, there was a non-significant decrease in LDL cholesterol (-0.25 ± 3.95 mg/dL, P
= 0.95). Also, there was a non-significant decrease in TG levels (-10.71 ± 10.28 mg/dL, P
= 0.34), SBP (-1.14 ± 1.08 mmHg, P = 0.30), and DBP (-1.40 ± 0.80 mmHg, P = 0.09).
Conversely, there was a non-significant increase in sodium excretion (3.38 ± 8.22
mmol/d, P = 0.68). Surprisingly, the entire group manifested a significant increase in
plasma ET-1 level instead of the anticipated decrease. Urinary levels of ET-1 increased,
as expected, by 0.79 pg/mL. However, this exercise training-induced change was not
significant.
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Table 7. Distribution and allele frequency of the ECE-1 polymorphism after AEX
Men Women Total
Genotype, % (n)
CC 25% (5) 6% (1) 19% (7)
CA 30% (6) 56% (9) 39% (14)
AA 45% (9) 38% (6) 42% (15)
Allele frequency
A allele 60% 66% 69%
Values are expressed as means ± SEM.
* Indicates significant (P < 0.05) exercise training-induced changes.
† Indicates significant (P < 0.001) exercise training-induced changes.
Table 8. Training-induced changes in overall group
N Change P-value
Body mass index, kg/m² 36 -0.34 ± 0.11 0.004*
VO2max, ml/kg/min 36 3.80 ± 0.45 <0.0001†
Total body fat, % 30 -1.87 ± 0.37 <0.0001†
Triglycerides, mg/dL 28 -10.71 ± 10.28 0.34
HDL cholesterol, mg/dL 28 3.00 ± 0.97 0.01*
LDL cholesterol, mg/dL 28 -0.25 ± 3.95 0.95
SBP, mmHg 28 -1.14 ± 1.08 0.30
DBP, mmHg 28 -1.40 ± 0.80 0.09
Sodium excretion, mmol/d 29 3.38 ± 8.22 0.68
Plasma ET-1, pg/mL 26 1.06 ± 0.44 0.02*
Urinary ET-1, pg/mL 23 0.79 ± 0.49 0.15
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Differences in Training–induced Changes
Residuals of plasma and urinary ET-1 were not normally distributed. Therefore,
these variables were log-transformed prior to analyses. As with baseline results, means
were presented using original data to allow for meaningful interpretation of results. As
shown in Table 9, all training-induced changes in all variables were not significantly
different (P > 0.05) between carriers of the C allele versus the AA homozygotes.
However, AA homozygotes experienced the greatest reductions in BMI, percent body fat,
and diastolic and systolic blood pressure, but again, these differences were not
statistically significant. They also experienced the least decrease in TG levels but the
most increase in sodium excretion. There was an unexpected increase in plasma levels of
ET-1 in the CA and AA genotype groups (Figure 3). As mentioned earlier, all these
changes were not statistically different among genotype groups. However, as with the
baseline results, there were significant gender differences in VO2max (P = 0.0013),
percent body fat (P = 0.01), and plasma ET-1 level (P = 0.04) changes with exercise
training (Data not shown). While men manifested no significant change in plasma levels
of ET-1 with AEX, women demonstrated a significant increase. There were no ethnic
differences in the main outcome variables. All analyses were covaried for baseline levels,
as well as variables that correlated with the variable of interest.
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Values are expressed as means ± SEM.
Numbers in parentheses represent sample sizes.
* Indicates significant (P < 0.05) exercise training-induced change.
† Indicates significant (P < 0.001) exercise training-induced change.
T Represents log-transformed data. Although means ± SEM of original data are shown, the P-value of
analyses with the log-transformed data was reported.
Table 9. Genotype differences in training-induced changes
Genotype
Characteristic CC + CA AA P-value






























































































Endothelin-1 (ET-1) is a potent vasoconstrictor and many lines of evidence
support its involvement in the regulation of blood pressure.23-28 Plasma levels of ET-1
have been found to be elevated in subjects with severe hypertension.29-34 On the other
hand, urinary levels of ET-1 have been found to be reduced in individuals with
hypertension.35, 36 Moreover, a study by Jackson et al.17 reported an association between
urinary levels of ET-1 and sodium excretion. This finding was particularly significant in
light of the fact that evidence clearly shows a strong association between abnormal renal
handling of sodium and blood pressure.37 Therefore, the main protease, endothelin
converting enzyme (ECE), responsible for the genesis of ET-1 by cleavage of its
functionally inactive precursor big ET-1 has been reported as a candidate gene for
essential hypertension.38 A polymorphism in this gene, ECE-1b-C-338A, has been
suggested to influence blood pressure. Only two studies thus far have investigated the
influence of this polymorphism on blood pressure.7, 8 Both studies found an association
of this polymorphism with blood pressure in females only.7, 8 In the study by Funke-
Kaiser et al.,7 ambulatory blood pressure measurement, which has been suggested to give
more valid blood pressure values for research purposes, was used. These investigators
found an association of AA homozygosity with higher blood pressure levels in 354
German women. Funalot et al., using casual blood pressure measurements, confirmed the
results of Funke-Kaiser et al. in 698 French women. Nonetheless, the current study found
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no association between this gene variant and casual systolic and diastolic blood pressure
in males and/or females even after accounting for age and body mass index (BMI). Age
and BMI were used as covariates because although these variables did not differ between
genotype groups, there was a tendency towards a significant correlation with systolic and
diastolic blood pressure. However, individuals homozygous for the A allele did have the
highest systolic and diastolic blood pressure values in the overall group, as well as in
males and females. However, these differences were not statistically significant. Since the
subject characteristics of all three studies were similar, the reason for the inconsistency in
the present study may be the small sample size, which may have rendered the study with
insufficient statistical power to detect differences between genotype groups.
Since blood pressure is a multi-factorial complex trait, intermediate phenotypes
(plasma and urinary levels of ET-1 and sodium excretion) were analyzed to determine
how the ECE-1 gene variant might perhaps influence blood pressure. It was hypothesized
that individuals homozygous for the A allele would have the greatest levels of plasma
ET-1 and lowest levels of urinary ET-1 and sodium excretion due to the association of
the A allele with higher promoter activity.
Plasma Levels of ET-1 
The levels of plasma ET-1 found in the current study are in agreement with
several other reports, falling in the range of 0.8 – 10 pg/mL.36, 39-41 However, the current
study found an association between the ECE-1b-C-338A polymorphism and plasma
levels of ET-1 in men only with AA homozygotes having the highest levels of plasma
ET-1 compared to carriers of the C allele (Figure 1). Because Funke-Kaiser et al.7 and
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Funalot et al.8 found an association between this polymorphism and blood pressure in
females rather than males, we anticipated an association of the polymorphism with
plasma ET-1 levels in females. The results of the present study contradict what was
expected. However, Funalot et al.8 reported similar blood pressure levels in CC
homozygotes and CA heterozygotes in women. Somewhat consistent with this result, we
found similar plasma levels of ET-1 in CC homozygote and CA heterozygote males,
signifying that the C allele might have a dominant effect. Ultimately, the contradictory
gender-specific genotype observations are difficult to reconcile and remain conjectural.
Evidence suggests a strong influence of gender on plasma levels of ET-1.
Estradiol inhibits ECE-1 gene expression and ET-1 synthesis.42-44 Consequently,
Polderman et al. showed that women have lower plasma levels of ET-1 in comparison to
men.45 Our data seems to be in disagreement with the previous result reported by
Polderman et al. because we did not find a significant gender difference in the levels of
plasma ET-1 in the overall group, nor within genotype groups. Instead, our results were
in accordance with a recent large epidemiological study by Hirai et al.46 who found no
gender difference in plasma ET-1 in 584 men and 866 women. However, the apparent
inconsistency in the present study and the study by Polderman et al. may be due to the
different subject characteristics (i.e. healthy young male-to-female and female-to-male
transsexual patients in the study by Polderman et al. vs. older hypertensive men and
women in the present study). Most importantly, while the subjects in Polderman’s study
were young healthy patients, the women in the present study were postmenopausal for >
2 years. Having lower estrogen levels, postmenopausal women tend to lose the beneficial
effects of this hormone, thus possibly increasing their plasma ET-1 to levels comparable
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to men. Nonetheless, in the present study, when women on hormone replacement therapy
(HRT) were compared with women not on HRT, there was no significant difference
between the two groups. This finding is not in accordance with a report by Ylikorkala et
al.47 who found that postmenopausal women on HRT had reduced plasma levels of ET-1.
Since the type, dosage, mode of delivery, and duration of HRT use was not standardized
in women on HRT in the present study, specific conclusions cannot be drawn. With
regards to experimental methods, most of the studies reported, (i.e. studies by Polderman
et al.,45 Hirai et al.,46 and Ylikorkala et al.47) measured plasma levels of ET-1 by
radioimmunoassay (RIA) and had cross-reactivity with big ET, ET-2, and/or ET-3
ranging from < 0.1% to 96%. In contrast, the current study utilized enzyme
immunometric assay (EIA) and had practically < 0.1% cross-reactivity with all isoforms
of ET but a 100% cross-reactivity with ET-1. These variations in methods, subject
characteristics, and even sample size, might explain the discrepancies in results.
Systemic administration of ET-1 above physiological levels induces a prolonged
increase in blood pressure, suggesting a role in hypertension.48 In fact, some older studies
found a positive correlation between plasma levels of ET-1 and blood pressure.33, 34, 49
Although a few other studies did not find a significant correlation between these two
variables,40, 46, 50, 51 we found a slight negative correlation of plasma levels of ET-1 with
diastolic blood pressure in the overall group (r = -0.42, P = 0.03), as well as in the
“CC+CA” group (r = -0.54, P = 0.02) after log transformation. This result suggests a
possible inverse relationship between plasma levels of ET-1 and diastolic blood pressure,
a finding that is counterintuitive and in disagreement with published results. Although
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there is great variability, studies suggest normal or only slightly increased levels of
plasma ET-1 in hypertensive animals and humans.39, 52, 53
Physiological levels of ET-1 are so low that they do not produce any vascular
effects. Under “physiological” conditions in the vessel wall, ~80% of ET-1 is released
abluminally by endothelial cell predominantly on the underlying VSMC.7, 54 Only 20% of
ET-1 produced by endothelial cells is secreted luminally and, thus, ends up in the
circulatory system.16 Furthermore, circulating ET-1 may be eliminated through the
kidneys, lungs, and/or liver.55-58 This suggests that ET-1 acts as an autocrine/paracrine
system rather than a systematic peptide.7 Also, worthy of attention is the fact that plasma
levels of ET-1 reflect partly ET-1 produced in other organs. Since plasma levels of ET-1
are a result of “spillover into the blood stream”59 and do not necessarily reflect ET-1
synthesis and/or secretion occurring in tissues,59 assessment of plasma ET-1 seems not to
be an appropriate parameter7, 60 for ECE activity and blood pressure levels (in
physiological states and pathological conditions of moderate intensity). Instead, new
techniques must be designed to enable the measurement of ET-1 at the vascular smooth
muscle interface and in tissues. Until then, reports from studies utilizing plasma ET-1 as a
marker should be interpreted with caution.
Urinary Levels of ET-1 and Sodium Excretion
As we discuss urinary and sodium excretion findings from the present study, bear
in mind that unlike plasma levels of ET-1, urinary levels of ET-1 represent ET-1
synthesis in the kidneys. Thus, urinary ET-1 excretion is a marker of nephron ET-1
metabolism.11 In the nephron, ET-1 acts in an autocrine manner to directly inhibit sodium
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and water reabsorption.11 Hence elevated levels of renal ET-1 will promote natriuresis
and favor hypotension, while a reduction would favor sodium and water retention, and
contribute to a hypertensive state.
There is great variability in reported “units” of urinary ET-1. In order to compare
mean urinary levels of ET-1 in hypertensives subjects across studies, units in this study
and other studies were converted to ng/day. Studies have reported levels of urinary ET-1
in hypertensives ranging from 0.03 ng/day61 to 29 ng/day36. The mean concentration of
4.96 ng/day (2.21 pg/mL) urinary ET-1 in the present study falls within the range
reported above. Furthermore, this value is similar to values (4.38 ng/day) found in the lab
of Ferri et al.62 Similarly, the average 24-hour sodium excretion rate in the overall group
(112.69 mmol/d) in the present study was within normal range.
No previous study has investigated the influence of the ECE-1b-C-338A
polymorphism on urinary excretion and/or sodium excretion, although one earlier study
has investigated the influence of salt intake on the expression of ECE in the renal
medulla.63 In this study, Fattal et al.63 found elevated expression of ECE-1 mRNA and
ECE-1 immunoreactive protein in the renal medulla of Wister rats exposed to high salt
diet than in rats on a normal salt diet.63 This suggests that increased salt intake up-
regulates ECE-1 expresssion.63 Thus, polymorphisms in ECE most likely result in
reduced ET-1 production leading to an inadequate natriuretic response to salt loading.63
Impaired renal ET-1 generation has been reported in patients with essential hypertension,
especially in the salt sensitive compared to salt resistant types.63, 64 Specifically, urinary
ET-1 level has been reported to be lower in hypertensive humans and rats.35, 36, 65, 66
Based on these findings, it seems that salt loading, rather than hypertension, upregulates
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ECE-1 expression in the medulla.63 Accordingly, studies have documented a positive
association between urinary ET-1 and sodium intake.67, 68 Thus, we expected sodium
excretion to be correlated with urinary excretion and be associated with this gene variant.
Such correlations and associations were not found in the current study.
In addition, the current study found no significant association between urinary
levels of ET-1 and this gene variant. Neither was there a significant gender specific
genotype association between these variables. Furthermore, while we found no gender
difference in the levels of urinary ET-1, there was a tendency towards a significant ethnic
difference in urinary levels of ET-1. African Americans had higher urinary levels of ET-1
compared to Caucasian men; however, this difference was of borderline statistical
significance (P = 0.05). Since urinary levels of ET-1 tend to be lower in hypertensives in
comparison to normotensives36 and hypertension is more prevalent in African American
men, we expected African American men to have lower levels of urinary ET-1 even if
these differences were not statistically significant. However, the initial blood pressure
values of African Americans in the present study may explain this discrepancy in results.
As reported previously, blood pressure values did not differ significantly among ethnic
groups; however, African Americans (both men and women) in our study had the lowest
systolic blood pressure. Although these differences were not statistically significant,
based on the blood pressure values, we would expect to see greater urinary ET-1 levels in
African Americans. Interestingly, we found no statistically significant gender differences
in sodium excretion, although men had much greater sodium excretion levels (131.27 ±
13.83 vs. 92.25 ± 10.57, P = 0.37 after log transformation). In addition, we found no
ethnic differences in sodium excretion in the overall group and in men and women.
36
Studies suggest a strong association between altered renal sodium handling and
high blood pressure.37 Particularly, reduced sodium excretion may increase blood
pressure by increasing blood volume. We found sodium excretion to be significantly
correlated with diastolic blood pressure (r = 3.7, P = 0.03) but not with systolic blood
pressure (r = 0.27, P = 0.11). However, we did not find a significant association between
urinary ET-1 and blood pressure. This latter finding is in accordance with data from the
labs of Lemne et al.33 and Hoffman et al.36 Hoffman and colleagues found a weak
negative correlation between mean arterial pressure and urinary ir-ET-1 levels only when
his controls and hypertensive subjects were grouped together.36 Otherwise, Hoffman
found no correlation between urinary levels of ET-1 and blood pressure in his
hypertensive subjects.
Additionally, we found no relationship between urinary levels of ET-1 and
sodium excretion. This finding is somewhat in disagreement with reports from the labs of
Hwang et al.69 and Saito et al.32 Both investigators found a positive correlation between
urinary ir-ET-1 and sodium excretion rate in patients with essential hypertension. In
addition, using 24-hour ambulatory blood pressure monitoring, Hwang et al.69 found that
urinary sodium excretion showed a rhythm similar to blood pressure, and urinary ET-1
excretion rate paralleled the sodium excretion rate in both normotensives and
hypertensives. They also showed increased urinary ir-ET-1 excretion rate in response to
saline loading in normotensive and hypertensive subjects. One reason that may explain
the discrepancies in results is the small sample size in the present study. Furthermore,
most studies discussed in this section measured ir-ET-1. Immunoreactive ET-1 is a
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combination of ET-1, big ET-1, and ET-2.70 Hence, assessments of ET-1 in the currents
study versus the older studies are different.
Aerobic Exercise Training-induced Changes
Blood Pressure
In the present study, we observed non-significant reductions in systolic and
diastolic blood pressure (SBP and DBP) in the overall group (-1.14 ± 1.08 mmHg and -
1.40 ± 0.80 mmHg, respectively) with AEX. The reductions observed in the present study
are small in comparison to those reported in reviews by Hagberg et al.71 and Brown et
al.72 (i.e. reductions of ~10 mmHg in SBP and ~8 mmHg in DBP). The remarkable
differences in the amount of reduction observed can be attributed to initial blood pressure
values of subjects in the studies. The average baseline SBP and DBP of the subjects in
the studies used in the review by Hagberg et al. and Brown et al. were > 140 mmHg and
> 90 mmHg, respectively.71, 72 Conversely, the average baseline blood pressure of the
subjects in the present study was 133/88 mmHg. Since reductions in blood pressure are
most pronounced in individuals with severe hypertension,73 we expected to see smaller
reductions. High intensity exercise training is less effective in reducing blood pressure.
However, lower training intensities have been consistently shown to effectively reduce
blood pressure.71, 74 Thus, the intensity of 70% of VO2max, used in the current study,
may have blunted the magnitude of changes experienced in this study group.
Because evidence suggests that exercise training reduces blood pressure in
humans, and even more so, in individuals with severe hypertension, we hypothesized
those individuals homozygous for the A allele, having the highest initial blood pressure
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values, would experience the greatest reductions in blood pressure. However, we
observed similar non-significant reductions in systolic and diastolic blood pressure in
both genotype groups (P = 0.28 and 0.65, respectively). Although the absence of a
significant genotype difference in the reductions experienced with AEX may indicate that
this gene polymorphism does not influence AEX-induced changes in blood pressure
levels in pre- and stage 1 hypertensives, this premise may not be valid due to the exercise
intensity utilized and the small sample size.
Plasma Levels of ET-1 
 The current study found an unexpected significant increase in plasma levels of
ET-1 after 24 weeks of AEX (1.06 ± 0.44, P = 0.02). The finding is not in accordance
with the reports of Callaerts-Vegh et al.,75 and Maeda et al.15, 16 While Callaerts-Vegh et
al.75 reported no change in plasma levels of ET-1 after eight weeks of AEX in patients
with congestive heart failure (n = 9), Maeda et al. reported reduced plasma levels of ET-1
with AEX in healthy normotensive young men (n = 7),15 and older healthy women (n =
8).16 Differences in their observations may be due to the difference in subject
characteristics i.e. patients with a cardiovascular disease vs. healthy subjects. Also, in
comparison to the current study (n = 26), the studies by Callaerts-Vegh et al.75 and Maeda
et al.15, 16 had small sample sizes where a single subject could have dramatically
influenced results. In addition, Otusuki et al. found plasma ET-1 levels to be lower in
endurance trained athletes compared to strength trained athletes (1.1 pg/mL vs. 1.6
pg/mL).76 Evidence suggest that nitric oxide (NO) production and bioavailability12, 77-80
and plasma prostaglandin E (PGE2)
81 is elevated with AEX. Since NO and PGE2 are
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inhibitory factors of ET-1, one could postulate that exercise training would reduce ET-1
production by the endothelium. However, a case could be made for increases in plasma
levels of ET-1 observed with AEX.
Evidence suggests that oxidative stress increases ET-1 production.82, 83 Moreover,
high-intensity AEX (≥ 75% of VO2max) has been found to possibly increase oxidative
stress.84, 85 Thus, high-intensity AEX possibly increases ET-1 synthesis. However, since
plasma levels of ET-1 most probably does not reflect the synthesis of ET-1 in the
vasculature, interpretation of previous and current data is compromised and the reason for
the discrepancies in results is hard to reconcile. Further studies in larger populations are
required to verify these results and to shed more light on the complex interactions among
ET-1, oxidative stress, shear stress and AEX.
While there was a tendency towards a significant increase in plasma ET-1 levels
in CA heterozygotes (P = 0.06), there was a non-significant increase in AA homozygotes
(P = 0.10) and a non-significant reduction in CC homozygotes (P = 0.92) (Figure 3).
However, statistical analysis revealed that these differences were not statistically
significant. Thus, this gene variant, most likely, does not influence training-induced
changes in plasma levels of ET-1.
Urinary Levels of ET-1 and Sodium Excretion
We found no significant increases in urinary ET-1 and sodium excretion with
AEX in the overall group. Both findings confirm preliminary results attained from this
lab. No previous study has reported the influence of AEX on urinary levels of ET-1, 
although published data from our lab reported a non-significant increase in sodium
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excretion with AEX.86 Exercise training has been documented to reduce blood pressure in
hypertensives.71, 87, 88 Although research has shed some light on mechanisms responsible
for AEX-induced reductions in blood pressure in hypertensives, there is still more to be
elucidated. One of the mechanisms through which AEX may work to reduce blood
pressure may be its influence on intrarenal ET-1 production and/or sodium excretion and
the complex interactions between these two systems. Given that ET-1 affects renal
sodium handling, and consequently blood pressure, the present study investigated the
influence of this gene polymorphism on sodium excretion. We found no genotype
differences in the AEX-induced changes. Neither did we observe gender-specific
genotype differences. This finding suggests that this gene variant may not be associated
with urinary levels of ET-1 and sodium excretion.
Limitations
Although we utilized a highly specific EIA (100% cross-reactivity with ET-1 and
< 0.1% cross reactivity with other endothelin isoforms), the current study is limited by
small sample size, inability to measure ET-1 synthesis in the vasculature, influence of
ECE-independent pathways on ET-1 levels, different technicians conducting extractions
and assays, compliance of study subjects to the exercise training protocol outside the lab,
and inclusion of different ethnic groups when assessing genotype differences.
Many steps were taken to minimize confounding variables. For instance, subjects
were asked to maintain their body weight within 5% of their baseline body weight. This
precaution was taken so that only the effect of exercise training was examined. Subjects
who were not weight stable were excluded from analyses. This elimination further
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reduced our already small sample size. Thus, one of the main limitations of this study
was the small sample size, limiting the statistical power of this study to detect significant
differences between genotype groups. Future studies are required to duplicate this study
in larger populations.
Secondly, we were unable to effectively assess ET-1 synthesis in the vasculature.
As discussed previously, plasma level of ET-1 is a result of “spillover into the blood
stream”59 and does not reflect vascular synthesis of this peptide.
Thirdly, although urinary ET-1 level is a good marker of ET-1 production in the
nephron, there are many ECE-independent pathways that contribute to the genesis of ET-
189 both in the nephron and in the vasculature. As discussed by Reiterova et al.,90 other
enzymes besides ECE, for instance, chymase A, a major angiotensin II-forming
enzyme,91 and non-ECE metalloproteases, can synthesize ET-1.89 These pathways are
practically impossible to control in human studies. Currently, no available technique
exists that can eliminate their influence.
In addition, two different technicians performed ET-1 extractions, purifications,
and assays. Although results obtained were identical, personal differences in procedural
implementation may affect results.
Results obtained in this study can only be generalized to similar populations i.e.
non-smoking and non-diabetic hypertensive middle-aged to older adults who are free of
cardiovascular disease.
Furthermore, although subjects in this study were required to strictly follow the
prescribed exercise protocol, compliance outside of the lab could not be controlled.
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Last but not the least, genotype differences could not be performed in the various
ethnic groups. Thus, ethnic differences may confound results.
Conclusion
It is not known how the ECE-1b-C-338A polymorphism affects plasma and
urinary levels of ET-1 and AEX-induced changes in these variables. The present study
showed for the first time that this gene variant may be associated with plasma levels of
ET-1 in men but not with urinary levels of ET-1, signifying that the expression of this
gene variant differs in these two biological systems. Additionally, this polymorphism,
most likely, does not influence AEX-induced changes in these variables, suggesting no
relationship with AEX-induced changes in blood pressure. This finding is of empirical
importance, given that accumulation of studies on single nucleotide polymorphisms
would facilitate personalized exercise training prescription and/or programs in the near
future. However, this study needs to be replicated in larger populations. Additionally,




Hypertension, chronically elevated arterial blood pressure, affects one in three
adults in the United States.2 In the 2002 World Health Report, it was estimated that
approximately 7.1 million deaths per year may be attributable to hypertension.92 The high
prevalence of hypertension is unquestionable; however, the cause of 90-95 percent of the
cases of high blood pressure is not known (primary or essential hypertension).2
Secondary hypertension, which occurs when elevated blood pressure is a result of another
disease, such as renal hypertension, makes up the remaining 5-10 percent. Regardless of
the cause of hypertension, baroreceptor reflexes or any of the normal mechanisms that
regulate blood pressure cannot compensate for hypertension because under conditions of
chronically elevated pressure, the baroreceptors reset and the regulatory mechanisms
work to maintain the new, high pressure.1
Hypertension has several adverse effects on the cardiovascular system. Elevated
arterial blood pressure increases the workload on the heart, hence, it can increase the
likelihood of a myocardial infarction. It can also lead to heart failure because it increases
afterload (the pressure that the ventricles have to work against as they pump blood) and
can chronically elevate end-diastolic volume (the volume of blood contained within each
ventricle at the end of diastole). Hypertension-induced damage to blood vessels can also
lead to kidney failure and loss of vision.1 Consequently, hypertension is a major risk
factor for cardiovascular and renal diseases, such as coronary artery disease,
atherosclerosis, stroke, and kidney failure.
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Specific factors that elevate blood pressure include increased cardiac output, total
peripheral resistance, and blood volume. Elevated stroke volume and/or heart rate cause
cardiac output to increase, while vasoconstriction causes total peripheral resistance (TPR)
to increase. Failure of the kidneys to excrete adequate amounts of salt and water results in
the retention of excess fluid in the body. This excess fluid causes blood volume to
increase, which raises mean arterial pressure. Thus, any condition, genetic variation,
hormone, or peptide that inhibits or stimulates any of these factors will influence blood
pressure. One such peptide is endothlein-1, a potent vasoconstrictor. Consequently, a
genetic variant in the enzyme responsible for the production of endothelin-1 from its
precursor influences blood pressure.
Treatments for hypertension include pharmacologic interventions such as
diuretics, beta blockers, calcium channel blockers, and angiotensin converting enzyme
(ACE) inhibitors, and nonpharmacologic interventions such as exercise, dietary sodium
reduction, weight loss, and psychological stress management. Diuretics promote
increased excretion of salt and water by the kidneys, thus reducing blood volume and
blood pressure. Beta blockers reduce cardiac output while calcium channel blockers
reduce the flow of calcium into vascular smooth muscle cells (VSMC), which prevents
vasoconstriction and lowers TPR. ACE inhibitors lower TPR by reducing plasma levels
of angiotensin II, a potent vasoconstrictor. Aerobic exercise training (AEX) is a major
nonpharmacological method for treating hypertension. Specific mechanisms underlying
the reduction in blood pressure with AEX in individuals with hypertension are unknown.
However, AEX seems to modify many of the factors that influence blood pressure. For
instance, AEX reduces resting heart rate and heart rate at any given submaximal exercise
45
intensity. Although blood volume is increased with AEX, TPR is reduced.93 All of these
factors ultimately aid to reduce blood pressure.
As mentioned earlier, ET-1 is a potent vasoconstrictor that influences blood
pressure. Its potency is 10 times that of angiotensin II.94 Thus, elevated levels of ET-1 in
the vasculature increase TPR by its vasoconstriction action, ultimately having a
hypertensive effect. Interestingly, ET-1 action in the renal tubule has a hypotensive effect
by decreasing total blood volume.4 The discovery, general biology, and function of ET-1
will be discussed in the next section. Then a general review of the actions of ET-1 in the
vasculature and renal tubule will be presented after the discussion of a genetic variant in
the endothelin converting enzyme that may be associated with hypertension. Lastly, the
influence of acute exercise and aerobic exercise training will be presented.
Endothelin-1
Hickey et al. showed for the first time in 1985 the presence of a vasoconstrictor
peptide secreted by porcine aortic endothelial cells.95 This observation was confirmed by
Gillespie et al.96 and O’Brian et al.97 in 1986 and 1987 respectively. In 1988, Yanagisawa
and his colleagues isolated, sequenced, and cloned the endothelin (ET) peptide from the
supernatant of cultured porcine aortic endothelial cells.3 The structure of ET is very
unique and does not belong to any previously known mammalian peptide family, but is




The endothelin family consists of three ET isoforms, ET-1, ET-2, and ET-3. All
isoforms are made up of 21 amino acid residues and show complete similarity at ten
positions, including all four cysteine (Cys) residues, which are located at positions 1, 3,
11, and 15.100 These four Cys residues form two intrachain disulfide bonds (Cys1-Cys15
and Cys3-Cys11).3 Both the disulphide bonds and the C-terminal tryptophan (Trp)
residue are essential for its high affinity binding to its receptor(s) and biological
activity.101 All three ET isoforms are synthesized as larger preproforms, which are the
primary translation product.100 Processing of the 212 (human) amino acid prepro-ET
peptides occur in three stages. First, neutral endopeptidase (NEP) cleaves prepro-ET at
Arg52-Cys53 and at Arg92-Ala93. Carboxypeptidase then sequentially trims the Arg92 and
Lys91 residues from the COOH terminus to produce propeptides called big ET. Finally,
big ET-1, a 38 (human) or 39 (porcine) amino acid residue, is cleaved at the Trp73-Val74
bond to form the final 21-amino acid ET peptide by endothelin converting enzyme (ECE)
located in the plasma membrane.6, 94 Apparently, cleavage of propeptides by ECE is
insufficient in vivo and in vitro because big ETs are present in plasma and in the media of
cultured cells.100, 102 Secreted ET stimulates the secretory cell itself (autocrine) and/or
neighboring cells (paracrine).4
Endothelin-1 Gene
The three isoforms of ET, ET-1, ET-2, and ET-3, are encoded by three distinct
genes on different chromosomes.103-108 ET-1, the predominant isoform and the focus of
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this paper, is the most powerful natural vasoconstrictor substance known.6 It appears to
be the ET isoform responsible for most of the pathophysiology associated with alterations
in ET production. In humans, the ET-1 gene has been mapped to chromosome 6p23-24
and the complete nucleotide sequence is known. The gene spans 6836 bp of DNA, and
contains five exons, four introns, and 5′- and 3′-flanking regions.109-112
While the coding region of ET-1 gene is 6.8 kb in length, the primary transcript,
ET-1 mRNA, which directs translation of the precursor preproET-1 peptide, is 2.3 kb in
length.100 The human ET-1 mRNA has a half-life of approximately 15-20 minutes,
possibly due to three AUUUA motifs in the 3′ non-translated region that may mediate
mRNA destabilization.6, 112, 113 The five exons of the ET-1 gene encodes a portion of
preproET-1. For instance, exon 1 encodes the 5′-untranslated region and the first 22
amino acids of the precursor including the entire signal sequence.100, 114 Exon 2 encodes
the sequence for the mature ET-1 peptide, the Trp-Val cleavage site at which ECE
processes big ET-1, and the first four residues of the COOH-terminal portion of big ET-
1.100 Exon 3 contains the coding region of the remainder of big ET-1, while exon 5
specifies the COOH-terminal portion of preproET-1 and the 3′ untranslated region of the
mRNA.100 The ET-1 promoter has two functional transcription start sites115 and several
important regulating sequences, including TATAA and CAAT boxes, and binding sites
for nuclear factor-1 (NF-1), acute phase reaction regulatory elements (APRE), GATA
motif, and AP1 sequence.100 The GATA motif recognizes zinc finger DNA-binding
proteins, while octanucleotide AP-1 sequence binds proto-oncogene products such as c-
fos and c-jun complexes.113
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So to reiterate the process of ET-1 production, transcription of the ET-1 gene by
ET-1 mRNA leads to the production of the 212 amino acid PreproET-1.113 PreproET-1 is
hydrolytically cleaved by NEP to form big ET-1, which is then cleaved by ECE to form
ET-1.6, 94
Endothlein-1 Gene Expression and Regulation
ET-1 is produced in almost all cell and tissue types. For instance, endothelial cells
appear to express ET-1 mRNA.100 ET-1 gene expression also occurs in other cells types
such as epithelial cells,116, 117 keratinocytes,118, 119 macrophages,120 bone marrow mast
cells,121 astrocytes,122 cardiomyocytes,123 and mesangial cells.124 Additionally, ET-1
expression has been observed in tissues such as the lungs, brain, uterus, stomach, heart,
adrenal gland, and kidney.125, 126
The regulation of the transcription of ET-1 mRNA seems to play an important and
probably predominant role in the regulation of gene expression.100 Thus, it has been
suggested that ET-1 secretion is determined largely by the levels of transcription and
translation.113 Agents that stimulate the release of ET-1 by enhancing ET-1 mRNA
expression fall into three categories: vasoconstrictors/thrombogenic agents, inflammatory
cytokines, and physical factors.113 Vasoconstrictors/thrombogenic agents such as
thrombin,127 angiotensin II,128-130 vasopressin (AVP),130 and ET-1 itself130 increase
endothelial cell ET-1 release via sequential activation of phosphorylase C, protein kinase
C (PKC), c-Jun/c-Fos, and the AP-1 site in the ET-1 promoter.113 Examples of
inflammatory agents that stimulate ET-1 release are cytokines such as interleukin-1 (IL-
1),127 transforming growth factor β (TGF-β),130-133 and tumor necrosis factor (TNF).127,
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134-136 Finally, some physical factors that elevate endothelial cell ET-1 production are
mechanical strain and low shear stress (5 dynes/cm2).113, 137 Conversely, ET-1 release is
inhibited by anticoagulants and vasodilators such as heparin, bradykinin, prostaglandin E2
(PGE2), prostacyclin (PGI2), atrial natriuretic peptide (ANP), and nitric oxide (NO).
5, 113,
138 High shear stress (25 dynes/cm2) also decreases ET-1 mRNA expression.139, 140
Endothelin-1 Receptors
Both endothelin A (ETA) and endothelin B (ETB) receptors are G protein-coupled
receptors. Thus, they contain seven hydrophobic membrane spanning helices joined
together by three extracellular and three intracellular loops, an extracellular NH2-terminal
region and an intracellular COOH-terminal region.100 ETA receptors consist of 427 amino
acids and are found on vascular smooth muscle. ETB receptors contain 442 amino acids
and are found on both vascular smooth muscle and endothelium.113 Although ETA and
ETB receptors are identical in structure, they are encoded by two distinct genes spanning
40 and 24 kb of DNA, respectively.141-144 The human ETA gene is found on chromosome
4 and contains eight exons and seven introns, while the human ETB gene is located on
chromosome 13 and contains seven exons and six introns.100
Signal Transduction Mechanisms
When ET-1 binds to ETA or ETB receptors found on the vascular smooth muscle,
it leads to the formation of inositol triphosphate (IP3). The formation of IP3 leads to
calcium mobilization and smooth muscle vasoconstriction.6, 145 However, when ET-1 
binds to ETB receptors located on endothelial cells, it produces vasodilation (or
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vasorelaxation) through endothelial nitric oxide synthase (eNOS).6 Thus, ETB receptors
localized on endothelial cells participate in vasodilation, whereas ETA and ETB receptors
localized on vascular smooth muscles mediate vasoconstriction.
Endothelin-1 Receptor Agonists and Antagonists
The development of several ETA and ETB receptor antagonists and agonists has
helped confirm the operation of ET-1 receptors and holds promise for the treatment of
disorders associated with ET-1.5 Thus, the following is a list of agonists and antagonists
of ET receptors, some of which were utilized in various studies that will be discussed
throughout this document. Antagonists of the ETA receptor include BQ-123 and [Dpr
1-
Asp15]ET-1. An antagonist of the ETA receptor is IRL 1038ET-1. An antagonist of the
ETB receptor is BQ-788.
9 Cochinmicins and PD 145065 are antagonists of both ETA and
ETB receptors. Finally, some agonists of the ETB receptor are IRL 1620 and sarafotoxin
6c.113
As stated previously, the binding of ET-1 to ETA receptors produces
vasoconstriction. Accordingly, ETA receptor antagonists cause vasodilation. However,
ETA receptor antagonists produce a greater degree of vasodilation in forearm vessels of
essential hypertensive patients compared with normotensive subjects.146 On the other
hand, the binding of ET-1 to ETB receptors produce vasodilation through eNOS or
vasoconstriction through calcium mobilization in endothelial cells and VSMC,
respectively. Thus, although the ETB receptor antagonist BQ-788 induces
vasoconstriction and increases forearm resistance in normotensive subjects,147 it
stimulates a vasodilator action in the forearm circulation of hypertensive subjects.146
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Findings on the distribution of ET receptors in African Americans shed some light on this
seemingly contradictory finding. Apparently, in African Americans, who have an
increased prevalence of hypertension, there is a modification of the ratio between
endothelial and smooth muscle ETB receptors that may lead to an overall ETB-mediated
vasoconstrictor effect.148, 149 Specifically, Ergul et al.148 found that the total number of
ETB receptors was lower in black patients in comparison to white patients. Additionally,
black patients possessed both ETA and ETB receptor subtypes on vascular smooth muscle
cells, whereas white patients possessed only the ETA receptors on vascular smooth
muscle cells. Thus, it seems that a modification in the tissue distribution of ET receptors,
between vasodilatory and vasoconstrictor receptors, may partly explain the increased
prevalence of hypertension in African Americans.149 Likewise, this may explain for the
seemingly opposing effects of BQ-788 on blood pressure in normotensives and
hypertensives.
Functions of Endothelin-1 
Although ET-1 was originally reported to be produced by endothelial cells, it is
now evident that it is produced by many tissues and organs and exerts diverse biological
effects on every organ system.150 Some biologic actions of ET-1 include stimulation of
smooth muscle contraction as discussed above, cell proliferation, extracellular matrix
accumulation, diuresis, and natriuresis. ET-1 also causes bronchoconstriction3 and serve
as a neurotransmitter.151 Nonetheless, the vasoconstrictor property of ET-1 is the most
widely studied and best understood. For instance, it is now known that ET-1-induced
contractions of isolated blood vessels are more slowly developing and are maintained for
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a longer time in comparison to other vasoconstrictors such as angiotensin II.100 Functions
of endothelin-1 relevant to this paper are smooth muscle contraction, diuresis, and
natriuresis.
Endothelin Converting Enzyme
Endothelin converting enzyme (ECE) is a phosphoramidon-sensitive membrane
bound metalloprotease found on endothelial cell membrane. The ECE gene is located on
chromosome 1p36, spanning over 120 kbp and consisting of 20 exons.152-154 It cleaves
big ET-1 to ET-1 via proteolytic cleavage between a Trp and valine (Val) residue. There
are two different ECE isoforms, ECE-1 and ECE-2.7 ECE-1 is mainly expressed in the
vascular endothelium, while ECE-2 is expressed in neural tissues.7 ECE-1 exists in four
different isoforms (ECE-1a,155 ECE-1b,155 ECE-1c,156 and ECE-1d153) which differ by
their N-terminal amino acid tails, and result from the existence of four isoform-specific
alternative promoters in the gene encoding ECE-1. The N-terminal amino acid is
responsible for their cellular location.8
ECE-1b, the enzyme of interest in the present study, is an intracellular enzyme,
while the other isoforms have their catalytic domain toward the outside of the cell. The
ECE-1b isoform is expressed in endothelial and vascular smooth muscle cells and may,
therefore, contribute to vascular ET-1 generation. A genetic variation in the ECE-1 gene




A polymorphism of the ECE-1 gene, ECE-1b-C-338A, in the 5′-regulatory region
of the ECE-1 gene (338bp upstream from the translation start site), has been identified
that results in a binding site for the transcription factor E2F-2 and GATA proteins.7, 9
ECE-1b-C-338A is associated with increased promoter activity, with the A-allele
showing an increase in promoter activity compared with the wild type promoter.9 Two
studies, one by Funke-Kaiser et al.7 and the other by Funalot et al.,8 studied this
polymorphism in two cohorts of hypertensive patients. In the study by Funke-Kaiser et
al.,7 the A-allele had a codominant effect on blood pressure in untreated hypertensive
German women. Specifically, these German women had a significantly higher daytime
and nighttime ambulatory systolic and diastolic blood pressure.7 In the study by Funalot
et al.,8 performed in a cohort of 1198 subjects (491 men and 698 women) from the French
epidemiological study Étude du Vieillissement Artériel (EVA), a similar association was
found in women. Since the AC heterozygotes had BP levels similar to those of CC
homozygotes, Funalot and his colleagues concluded that it suggests a recessive effect of
this gene variant in the population.8 If this is true, then AA homozygotes are expected to
have the highest levels of ECE-1 gene transcription and ECE-1 enzymatic activity. So,
while this gene variant seems to have a codominant effect in German women, it seems to
have a recessive effect in French women.
As shown by the experiments discussed above, the A-allele is associated with
higher promoter activity.8 Since the ECE-1 gene appears to be the rate-limiting enzyme in
the biosynthesis of mature ET-1 in vivo, it has been suggested that the enhanced
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expression of the enzyme (i.e. in AA homozygotes) could increase ET-1 synthesis in the
vessel wall.90 However, this is yet to be proven. This present study will seek to confirm
this association. Also, ET-1 has been suggested to be a disease promoting factor in the
kidney.90 In a study by Reiterova, Merta, and Stekrova, there was a tendency toward
faster decline of renal function in AA homozygous individuals.90 However, the effect of
this polymorphism on renal-derived ET-1 is still yet to be elucidated. Moreover, the
reason why an association between this gene variant and blood pressure was observed
only in females is yet to be elucidated, but could be related to interactions between sex
hormones (estrogen) and the ET system. Stimulation of the ET system by androgens
could be an explanation for the lack of effect in males.9
Endothelin-1 in the Vasculature (Plasma ET-1)
In the vasculature, elevated ET-1 action predominantly causes vasoconstriction.
However, very low levels of ET-1 are found in the plasma due to a number of reasons.
First, circulating endothelin may bind to its receptors to produce its biological actions.
Additionally, it may be eliminated by pulmonary uptake.55, 56 Remaining portions may be
eliminated through the kidneys by NEP cleavage and a very small amount through the
liver.57, 58, 157 Hence, while the half-life ET-1 mRNA is 15-20 minutes, the half-life of
mature ET-1 in the plasma only range from 1-7 minutes.6, 70, 158-160 In a study by Anggard
et al., intravenously injected labeled ET-1 was quickly eliminated from the blood stream
showing that ET that is released is quickly eliminated and/or taken up and bound to one
of its two possible cell surface receptors.160, 161 Due to these low levels of ET-1 in the
plasma, extraction and purification are usually performed before assay to obtain more
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valid results.70 In humans and animals, levels of ET-1 and big ET-1 in the blood range
from 0.3 to 3 pg/ml, but there is a great deal of variablility.57, 102, 162, 163
Some investigators argue that plasma levels of ET-1 may not accurately reflect
changes in endothelial synthesis or the concentration of the peptide in the vascular wall
because other organs in the body may contribute to the circulating levels of ET-1, and the
majority of ET-1 derived from endothelial cells is released towards the vascular tunica
media70 and not the lumen. Evidence has confirmed that ET concentration at the
endothelium/smooth muscle interface where it is released is higher than in the
bloodstream.94 Nonetheless, levels of ET-1 in the plasma reflect a balance between its
production and clearance.70 So although ET-1 causes vasoconstriction, which increases
total peripheral resistance and hence blood pressure, studies measuring plasma levels of
ET-1 as a maker of elevated blood pressure produce conflicting results.
Consequently, some studies have reported elevated levels of plasma ET-1 in
essential hypertension,29-34, 164 while others have not.39, 53 Kohno et al.29 found that
plasma immunoreactive ET (ir-ET) is elevated in hypertensive individuals with severe
hypertension or renal involvement. In another study by Ergul et al.,30 both male and
female hypertensive blacks had significantly elevated levels of plasma ir-ET-1 compared
with normotensive control blacks. The difference in plasma ir-ET-1 between black
hypertensives and normotensives was approximately 10 pmol/L. Similarly, male and
female hypertensive whites had significantly elevated levels of plasma ir-ET-1 compared
to normotensive whites. However, the difference in plasma ir-ET-1 between the white
hypertensives and white normotensives was smaller (~ 1.5 pmol/L). In a case-control
study by Lemne et al.,33 they also found a significantly elevated plasma ir-ET levels in
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pre- and stage 1 hypertensives compared to age-matched normotensive men. However,
this difference was even smaller (~0.5 pmol/L).
With reference to the negative studies, Predel et al.53 found no significant increase
in plasma ET-1 in hypertensives compared to normotensives although the difference
between groups was ~1.1 pmol/L. Likewise, Haynes et al.39 found similar circulating ET
levels in hypertensives and normotensives. However, they found that patients with
essential hypertension had enhanced vasoconstriction to ET-1 that is positively correlated
with blood pressure. Nevertheless, Forgari et al.165 found that although plasma levels of
ir-ET-1 were not correlated with casual SBP and DBP in pre- and stage 1 hypertensives,
they where significantly correlated with 24-hour ambulatory blood pressure (both
nighttime and daytime SBP and DBP values), suggesting that the method of acquiring
blood pressure measurements may affect the results.
Elevated levels of plasma ET-1 have been observed in other cardiovascular and
renal conditions.113 However, there seems to be little or no correlation between plasma
ET-1 and blood pressure in pre- and stage 1 hypertensives except in the presence of other
diseases (such as renal diseases).166 It has been suggested that the high concentrations of
plasma ET-1 found in hypertension secondary to renal disease might be due to impaired
renal clearance of ET-1.39 Thus, most studies conducted in pre- and stage 1 hypertensive
patients with normal renal function tend to find concentrations of ET-1 similar to
normotensives.51, 58, 167 In the absence of other diseases, there seems to be an association
between plasma ET-1 and blood pressure in stage 2 hypertensives.
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Endothelin-1 in the Kidney (Urinary ET-1)
Research thus far has focused on two major areas of renal ET-1 involvement in
essential hypertension: the renal vasculature and renal tubules. Most cells in the renal
vasculature, such as endothelial, mesangial, and vascular smooth muscle cells, are
capable of producing ET-1.168-170 ET-1 stimulates mesangial cell and vascular smooth
muscle cell vasoconstriction through activation of ETA and ETB receptors.
171 However, it
stimulates vasodilation in endothelial cells through ETB receptors.
172 Infusion of ET-1
causes a reduction in glomerular filtration rate (GFR), in addition to its renal
vasoconstrictive effect.172 Specifically, increasing plasma levels of ET-1 from basal
levels to approximately 10 pmol/L causes a significant reduction in renal blood flow,
GFR, urinary flow rate, and sodium excretion.13 However, a study by Warren et al. found
no such correlation between plasma ET-1 and GFR.172 Although elevated circulating
levels of ET-1 have been reported by Anand et al. to reduce sodium excretion, which
would suggest an increase in blood volume resulting in hypertension,5 ET-1 action in the
nephron seems to decrease blood volume by enhancing sodium and water excretion,
favoring hypotension.19 In order to appreciate the function of ET-1 in the kidney, this
section will briefly discuss the production and major functions of ET-1 in the nephron.
Production of Endothelin-1 in the Kidney
A year after the discovery of ET-1 in porcine aortic endothelium, Berbinschi and
Ketelslegers reported finding ir-ET in human urine at concentrations six times higher
than those found in the blood.173 Since then, many studies have confirmed that the human
kidney is rich in ET-1174 and urinary ET-1 is of renal origin.175 Although every region of
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the kidney has been found to be potentially regulated by and produce ET-1, the renal
medulla emerges as the predominant ET-1 production site. ET-1 synthesis is high in the
inner medulla, and less within the outer medulla (inner stripe > outer stripe), and
markedly decreased in the cortex. The production of ET-1 in the medulla exceeds that of
anywhere else in the human body.5 Within the inner medulla, the inner medulla
collecting duct (IMCD) is clearly the major source of ET-1,176 producing 10-fold more
ET-1 than any other nephron segment.150 Renal ET receptor expression parallels that of
ET-1 synthesis, with the greatest receptor expression in the inner medulla. The medulla
expresses the greatest density of ETB receptors within the kidney.
113 Because the medulla
is the predominant site of ET-1 production and receptor expression in the kidney, this
section largely discusses the synthesis and action of ET-1 in the medulla. The net effect
of ET-1 in the renal medulla is diuretic and natriuretic.177, 178
Again, very little circulating ET-1 appears in the urine because the kidney has
several degrading enzymes in the proximal tubule that contribute to renal clearance of
ET-1 from the blood.177 Abassi et al. found that the clearance of 125I-labeled ET-1 from
the blood into the urine is very low.19 Specifically, only 0.2 – 0.3% of the total
radioactivity injected as 125I-ET-1 into normal rats was recovered in the urine within 30
minutes.19 However, when rats were treated with neutral endopeotidases (NEP) inhibitors,
a significantly elevated amount of 125I-ET was recovered in the urine suggesting that
filtered ET-1 is subject to proteolytic degradation by NEP.19 As explained in the review
by Abassi et al., NEP is predominantly located along the brush border of the proximal
tubules and has a very high affinity for all isoforms of ET.19 Consequently, it is very
unlikely that urinary ET-1 is derived from the blood.19, 113
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Since urinary ET-1 is most likely of renal origin,179 it been proposed that urinary
ET may be a possible marker of renal disease/damage. Many studies support this claim.
For instance, urinary ET-1 is elevated in nephritic patients such as those with glomerular
disease,179 proteinuria,180 mesangial proliferative glomerulonephritis,181 focal segmental
glomerulosclerosis (prerequisite for renal failure),20 and progressive kidney disease due
to reduced kidney mass.19, 182
Function of Endothelin-1 in the Kidney
Endothelin-1 produced in the kidney is multifunctional and regulates a variety of
renal functions such as cell proliferation, extracellular matrix accumulation, renin release,
blood flow, and electrolyte and water transport.183, 184 Of interest in this review is ET-1’s
regulation of electrolyte and water transport. Definitive evidence from gene targeting
studies183 show that ET-1 inhibits its Na+/K+ ATPase activity and AVP-stimulated cAMP
generation that results in decreased AVP-dependent water absorption. In a study by Ge et
al.,184 collecting duct ET-1 knockout mice could not eliminate an acute volume load as
well as wild-type mice. However, there was no difference in the ability of the two strains
to eliminate a chronic water load. This study and another similar study by Ahn et al.19
show unequivocally that under physiological circumstances, ET-1 produced in the
collecting duct promotes diuresis. Data on similar experiments in pathological conditions
such as hypertension are not available.
ET-1 also modulates sodium transport by the collecting duct. A high sodium diet
increases medullary ET-1 mRNA, medullary ECE-1 mRNA, and protein.185 Thus, these
in vivo studies suggest that medullary ET-1 reduces blood pressure by inhibiting sodium
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and water reabsorption. Moreover, it appears that it is the ETB receptor that mediates
these known actions of ET-1 in IMCD. Generally, it is believed that in the kidney, ETA
receptors mediate vasoconstriction while ETB receptors mediate other functions.
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Reduced urinary ET-1 has been observed in rats and individuals with
hypertension. Hughes et al. found significantly reduced levels of urinary ET-1 in SHR
compared with values obtained in age-matched WKYs.35 Before the development of
hypertension, levels of urinary ET-1 in both rats were similar.35 It has been suggested that
there is a reduction in the synthesis of ET-1 in the kidney after the onset of hypertension
because cultured IMCD cells from SHR released less ET than those from WKY.186-188
Zoccali et al.34 found that ET-1 excretion in essential hypertensives and in normal
subjects were significantly lower than in renal hypertensives. They concluded that
synthesis of ET-1 in the nephron is elevated in individuals with hypertension secondary
to renal disease34 but not in individuals with essential hypertension.
As proposed by Serniri et al.189 elevated levels of ET-1 in the plasma above
physiological values may influence renal regulation of blood pressure by reducing
urinary volume and sodium excretion via the vasoconstrictor activity of ET-1 at ETA
receptors (especially in the vasa recta, arcuate arteries, and in the peritubular capillaries).
On the other hand, elevated levels of ET-1 in the nephron may counteract the effect of
AVP and of renal vasoconstriction via ETB receptor mediated operations.
189 and
contribute to the maintenance of urine flow, causing an increase in free water
clearance.189 These seemly conflicting operations of ET-1 may work together to maintain
blood pressure in physiological conditions.
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Effect of Acute Exercise and Exercise Training
Acute Exercise, Plasma and Urinary Endothelin-1 
Studies on the effect of acute exercise on plasma levels of ET-1 have been fairly
consistent. Circulating ET-1 is slightly elevated immediately after acute exercise of
moderate intensity in humans and animals with and without cardiovascular and renal
disease.
Most studies found an increase in plasma levels of ET-1 immediately after an
acute bout of exercise59, 186, 187, 189-194 while some others have not.195, 196 Maeda et al.186
found that venous plasma levels of ET-1 were increased after ergometer cycling at 90 and
130% of the ventilatory threshold in intercollegiate athletes with the greatest increase at
30 minutes after exercise at both intensities. They concluded that the greater the intensity
of exercise, the greater the increase in plasma ET-1 concentration. Also, Predel et al.190
found elevated levels of plasma ET-1 in patients with coronary artery disease five
minutes after ergometer cycling. In another study by McKeever et al,191 plasma ET-1
levels were significantly elevated immediately and two minutes after steady state exercise
at 60% of VO2max in horses; however, these levels were unchanged during a graded
exercise test. These and other studies by Maeda et al.,192, 193 Mangieri et al.,194 Serneri et
al.,189 and Miyauchi et al.187 have confirmed that plasma levels of ET-1 are elevated
immediately after acute exercise of moderate intensity. Nonetheless, Cosenzi et al.195
found that plasma levels of ET-1 were not affected by 15 minutes of moderate intensity
ergometer cycling in young healthy individuals. Additionally, Cruden et al.196 found no
change in circulating levels of ET-1 24 hours after low altitude mountaineering in healthy
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males. These differences in results are not difficult to reconcile considering that the
duration of the exercise protocol in the study by Cosenzi was only 15 minutes and the
length of time that elapsed prior to plasma ET-1 testing in the study by Cruden et al. must
have been enough to allow circulating ET-1 to return to baseline levels. A few
inconsistencies that may not be easily reconciled are the observations of Matsakas et
al.197 and Lewczuk et al.198 The former observed opposite effects of acute exercise on
plasma levels of ET-1 in the trained and untrained groups (reduced vs. elevated,
respectively), while the latter found a significant increase and decrease in plasma levels
of ET-1 after jogging and cycling, respectively. Serneri et al. suggested and showed that
the reduction in blood volume that accompanies exercise is responsible for the increase in
ET-1 concentration in plasma. Thus, their study,189 and all other studies186, 187 that
measured and found a reduction blood volume with their exercise protocol, observed an
increase in plasma levels of ET-1.
While many studies have confirmed that plasma levels of ET-1 are elevated
immediately after acute exercise, there is conflicting data on changes in plasma levels of
ET-1 during exercise. Some studies found an increase in plasma ET-1 during exercise,188,
199 while one did not.200 For instance, Letizia et al.188 found an increase in plasma ET-1 in
patients with coronary artery disease who showed no ECG signs of myocardial ischemia
performing moderate intensity exercise. However, these values returned to baseline levels
during a six minute recovery period. Moreover, they found no change in plasma levels of
ET-1 at peak exercise and during the recovery period in normal subjects. All the same,
Ahlborg et al.199 found an increase in plasma ET-1 in healthy subjects performing
moderate intensity exercise. Conversely, Richter et al.200 found that forearm venous
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plasma levels of ET-1 declined in healthy men during the first 30 minutes of ergometer
cycling at 65% of VO2max; however, they increased back to resting values after 60
minutes of exercise.
Although there are studies on the effect of acute exercise on plasma ET-1, there
seems to be little data available on the effect of acute exercise on urinary ET-1. To the
best of the author’s knowledge, the only study available was conducted by Serneri et
al.189 In this study, the investigators found increased renal ET-1 with acute exercise.
Aerobic Exercise Training, Plasma and Urinary Endothelin-1 
The effect of aerobic exercise training (AEX) on plasma levels of ET-1 has also
been fairly consistent. The trend has been a reduction in the levels of plasma ET-1 with
AEX.15, 16, 59 However, there is one study75 that found no change in circulating levels of
ET-1 after AEX. Maeda et al., through a succession of studies, found that plasma ET-1 is
higher in middle-aged than in young men and it is significantly decreased by AEX in
healthy young men,15 and older women.16 Also, AEX prevented the increase in plasma
levels of ET-1 induced by acute exercise in normotensive offspring of hypertensive
patitents.59 The only study that found no change in plasma levels of ET-1 after AEX was
conducted in patients with congestive heart failure after acute myocardial infarction.75
Thus, there is available data on the effect of AEX on plasma ET-1 that show that AEX
reduces circulating levels of plasma ET-1. However, other investigators need to verify
this finding.
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To the best of the author’s knowledge, there are currently no published data on
the effect of AEX on urinary ET-1. Nevertheless, preliminary data from our laboratory
suggest that AEX causes a non-significant reduction in urinary levels of ET-1.
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